EDIUNET Free equity investment tool of Japanese companies

Companies Cart
@
Credit Rating Analysis
Annual
First quarter
Second quarter
Third quarter
Sponsored Link
Related Company
@ キョーリン製薬ホールディングス
@ 持田製薬
@ Otsuka Holdings
@ アステラス製薬
@ エスケー化研
@ Aica Kogyo
@ ONO PHARMACEUTICAL
@ 長谷川香料
@ Kuraray
@ Nichi-Iko Pharmaceutical
@ TSUMURA & CO.
@ 東京応化工業
@ Hitachi Chemical
@ Fuso Pharmaceutical Industries
@ Sekisui Chemical
EDIUNET Related Ranking
EDIUNET
EDIUNET Credit Rating
EDIUNET Industry Avg
EDIUNET Prefectures
Yuho! Industry
EDIUNET Rating News
Prev « 2024-03 » Next
Mon Tue Wed Thu Fri Sat Sun
1
-
2
-
3
-
4
-
5
-
6
-
7
-
8
-
9
-
10
-
11
-
12
-
13
-
14
-
15
-
16
-
17
-
18
-
19
-
20
-
21
-
22
-
23
-
24
-
25
-
26
-
27
-
28
-
29
-
30
-
31
-
[Update list]
1/28 Retail Trade (CAWACHI:A etc...
1/27 Banks (The Awa Bank:BBB→A)
1/23 Chemicals (Milbon:AA→AAA)
1/21 Glass & Ceramics Products (..
1/21 Machinery (TSUDAKOMA:C)
1/21 Other Services (Netindex.:CC)
1/20 Other Products (Kurogane Kos..
1/20 Wholesale Trade (リーバイ・..
1/20 Other Services (川崎地質:BB→..
1/17 Chemicals (Kawaguchi Chemica..
 RSS
 Company RSS
 Daily RSS
Sponsored Link
Recently Download Chart
Hitachi Zosen etc.
graph
メルコホールディングス
graph
KIKUSUI ELECTRONICS etc.
graph
KIKUSUI ELECTRONICS etc.
graph
クラリオン
graph

Credit Rating Analysis: キョーリン製薬ホールディングス (Annual )

The details of credit rating (bankruptcy risk) can be checked. A credit rating in nine stages (AAA-C).

【Analysis Menu】 @Outline @Statement @Rating @Indicator @Download

Sponsored Link

Credit Rating (Bankruptcy Risk): キョーリン製薬 HLDGS (Annual ) Consolidated | Non-Consolidated

Date Credit Rating Comment Sales Current Profit Net Income
2013-03-31  A  Credit is high, but affected by biz environs. ¥ 107 B
3.68%
¥ 18 B
22.26%
¥ 12 B
34.56%

Financial Timeline

Date  2012-12-31 
(Third quarter )
 2013-03-31 
(Annual )
 2013-06-30 
(First quarter )
 2013-09-30 
(Second quarter )
Credit Rating AAAAA
Total Assets
¥ 152 B
¥ 154 B
¥ 157 B
¥ 155 B
Net Assets
¥ 124 B
¥ 129 B
¥ 128 B
¥ 130 B

Financial Statement Risk Analysis: キョーリン製薬 HLDGS (Annual ) (Consolidated )

Special note
Net Assets have increased 5consecutive terms. The fiscal base is getting better.
[Date: 2013-03-31]  Danger : Warning : Caution : Good
Financing Good (*Operating Cash Flow is plus )
Investment Cash Flow (¥ -7 B) & Financial Cash Flow (¥ -5 B) is a minus, Operating Cash Flow (¥ 11 B) is a plus,
Dividend
Under the situation of Net Income (¥ 12 B) & Operating Cash Flow (¥ 11 B) , Dividend (¥ -3 B) is paid.
Non-performing asset Risk (*Accounts Receivable and Inventory, etc. confirmed content)
Other Current Assets first term ratio (¥ 8 B) is Sales first term ratio (¥ 3 B) more , there is a possibility that the non-performing asset was increased.
[Date: 2012-03-31]  Danger : Warning : Caution : Good
Management Risk (*Sales is decrease )
Sales (¥ 103 B) is first term Sales (¥ 104 B) less , there is a possibility that the management situation has stagnated and deteriorated
Management Risk (*Net Income is decrease )
Net Income (¥ 9 B) is first term Net Income (¥ 10 B) less , there is a possibility that the management situation has stagnated and deteriorated
Management Risk (*Net Profit Margin is decrease )
Net Profit Margin (8.94%) is first term Net Profit Margin (10.50%) less , there is a possibility that the profitability has deteriorated.
Financing Good (*Operating Cash Flow is plus )
Investment Cash Flow (¥ -4 B) & Financial Cash Flow (¥ -7 B) is a minus, Operating Cash Flow (¥ 8 B) is a plus,
Dividend
Under the situation of Net Income (¥ 9 B) & Operating Cash Flow (¥ 8 B) , Dividend (¥ -3 B) is paid.
Non-performing asset Risk (*Accounts Receivable and Inventory, etc. confirmed content)
Other Current Assets first term ratio (¥ -674 M) is Sales first term ratio (¥ -837 M) more , there is a possibility that the non-performing asset was increased.
[Date: 2011-03-31]  Danger : Warning : Caution : Good
Dividend
Under the situation of Net Income (¥ 10 B) & Operating Cash Flow (¥ 6 B) , Dividend (¥ -3 B) is paid.
Financing Risk (*Operating Cash Flow is decrease )
Sales (¥ 104 B) is first term (¥ 99 B) more, however Operating Cash Flow (¥ 6 B) is first term (¥ 12 B) less , there is a possibility that the financing has deteriorated very much.
Non-performing asset Risk (*Accounts Receivable and Inventory, etc. confirmed content)
Other Current Assets first term ratio (¥ 8 B) is Sales first term ratio (¥ 4 B) more , there is a possibility that the non-performing asset was increased.
[Date: 2010-03-31]  Danger : Warning : Caution : Good
Dividend
Under the situation of Net Income (¥ 8 B) & Operating Cash Flow (¥ 12 B) , Dividend (¥ -1 B) is paid.
[Date: 2009-03-31]  Danger : Warning : Caution : Good
Dividend
Under the situation of Net Income (¥ 2 B) & Operating Cash Flow (¥ 4 B) , Dividend (¥ -860 M) is paid.

Related Information: キョーリン製薬ホールディングス (Annual )

Statement Type
Annual : キョーリン製薬ホールディングス
First quarter : キョーリン製薬ホールディングス
Second quarter : キョーリン製薬ホールディングス
Third quarter : キョーリン製薬ホールディングス
Analysis Menu
@Outline : キョーリン製薬ホールディングス
@Statement : キョーリン製薬ホールディングス
@Rating : キョーリン製薬ホールディングス
@Indicator : キョーリン製薬ホールディングス
@Download : キョーリン製薬ホールディングス
Industry Comparison Ranking
Chemicals - EDIUNET Industry Rankings
Chemicals - EDIUNET Credit Rating
Chemicals - EDIUNET Industry Avg
Comparison with a neighboring company
Tokyo - EDIUNET Prefectures
Tokyo千代田区 - EDIUNET Prefectures

Related company's newest statement

Date Company Credit Rating Date
1/23 Milbon AA→AAA 2013-12-20
1/17 Kawaguchi Chemical Indu.. BBB→BB 2013-11-30
1/17 SANKEI CHEMICAL A 2013-11-30
1/15 HOKKO CHEMICAL INDUSTRY BB→B 2013-11-30
1/15 Daito Pharmaceutical Co . AA 2013-11-30 (Q2)
1/15 KAWAKAMI PAINT MFG. B→BB 2013-11-30
1/15 旭化学工業 AA 2013-11-30 (Q1)
1/10 OSAKA ORGANIC CHEMICAL .. BB→BBB 2013-11-30
1/10 HISAMITSU PHARMACEUTICAL A 2013-11-30 (Q3)
1/10 AMS Life Science BBB→BB 2013-11-30 (Q1)

Ticker Market Industry Month report Rating
@ キョーリン製薬ホールディングス 4569 TSE 1st Chemicals 3 Annual A

Related Company

@ Takeda Pharmaceutical (Sales ¥ 1.5 T)
@ NIPPON KAYAKU (Sales ¥ 128 B)
@ Dainippon Sumitomo Pharma (Sales ¥ 347 B)
@ Nissan Chemical Industries (Sales ¥ 153 B)
@ キョーリン製薬ホールディングス (Sales ¥ 107 B)
@ アステラス製薬 (Sales ¥ 1.0 T)
@ Aica Kogyo (Sales ¥ 101 B)
@ 東京応化工業 (Sales ¥ 72 B)
@ Hitachi Chemical (Sales ¥ 464 B)
@ The Nippon Synthetic Chemical Industry (Sales ¥ 91 B)
@ キッセイ薬品工業 (Sales ¥ 62 B)
@ ダイセル (Sales ¥ 358 B)
@ 持田製薬 (Sales ¥ 89 B)
Sponsored Link


関連する株式投資情報

EDIUNET Caution

*Financial data might be different from the actual one. Please confirm the original, and read Caution.

*This site has obtained the information from the FSA's EDINET, Tokyo Stock Exchange's TDnet and Pay statistical data services, Fukuoka stock Exchange's Stock market capitalization, Center for Spatial Information Science's CSV Geocoding Service. The copyright of the information belongs to each corporation etc. .

▲ Go to the top ▲

  1. Guide
  2. Mobile
  3. Tablet
  4. Japanese
`EDIUNET` Copyright©2006-2024 `MAバンク` (0.085 sec.)